NEW HAVEN, Conn. — September 17, 2025 — Leads & Copy — Invivyd, Inc. (Nasdaq: IVVD) has announced the appointment of Kristie Kuhl as Chief Communications Officer. Kuhl will lead the company’s communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease.
Kuhl brings expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications. She most recently served as Global Managing Director, Health & Wellness at Zeno Group.
“I’m thrilled to join Invivyd at such a pivotal time for the company, and for the patients and communities we serve,” said Kristie Kuhl, Chief Communications Officer at Invivyd. Marc Elia, Chairman of the Invivyd Board of Directors, added that Kuhl’s track record building high-impact healthcare narratives and leading teams through dynamic environments is critical to Invivyd as it moves forward with its mission.
Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates.
Contact:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
Source: Invivyd, Inc.
